ULBI ULTRALIFE CORP Insider Trading

Director Bradford T Whitmore bought 108,878 shares at blended $6.57 over 3 days; 5.6% portfolio increase amid unprofitable operations.

Director Bradford T Whitmore executed three separate purchases totaling 108,878 shares for $715,313.54 between 2026-05-21 and 2026-05-26, raising his holdings from 1,941,759 to 2,050,637 shares. The company's latest quarterly financials show revenue of $47,445,000.00 against net income of -$451,000.00, with annual revenue growth of +16.2% but full-year profitability still negative. At his prior trades at ULBI, 4 of 5 buys were well-timed at the 90-day mark, suggesting pattern recognition in his purchase timing at this ticker. The current stock price of $6.86 sits 27.9% below the 52-week high of $9.52 and down 9.1% over the past 30 days, though up 16.6% over 90 days—positioning this purchase in the context of recent price volatility and moderate-term gains.

ULBI CEO Manna buys 2,000 shares at $6.47; stock down 35.9% from 52-week high; prior 5 trades at this ticker all well-timed on 90d basis.

CEO Michael Edward Manna purchased 2,000 shares of Ultralife at $6.47 on 2026-05-18, expanding his holdings from 26,674 to 28,674 shares. The purchase occurs as the stock trades -35.9% from its 52-week high and is down 21.1% over the last 30 days, creating a contrarian buying signal. Notably, Manna's prior 5 trades at Ultralife were all well-timed at the 90-day mark (with 90d returns ranging from +0.6% to +28.5%), suggesting a consistent pattern of purchasing at strategically favorable entry points. However, context matters: the company remains unprofitable (net income $-451,000 in the latest quarter despite $47.4M in revenue and 16.2% annual revenue growth), and the stock has declined 1.9% over 90 days, meaning this purchase occurs in a materially different environment than his prior successes at this ticker.

CEO Manna Michael Edward purchased 2,000 shares at $6.01 blended average on 2026-03-12, expanding stake to 26,874 shares.

Michael Edward, President and CEO of Ultralife Corp, executed 2 separate purchases totaling 2,000 shares for $12,024.20, expanding his post-transaction holdings by 8.0% to 26,874 shares. His prior trade history at ULBI shows strong 90-day timing outcomes—4 of 5 prior buys were well-timed, with median 90d returns of +22.7% to +28.5% when excluding the -1.9% outlier. The stock has moved +9.2% in the 30 days since filing and +21.1% in the 90-day window, aligning with his historical pattern of acquisitions preceding periods of price appreciation at this ticker. However, the company reports net income of -$1.2M in the latest quarter against revenue of $43.4M, and carries a P/E of 70.10, warranting evaluation of whether the near-term price action reflects sustainable fundamentals or momentum that may not hold.

Director WHITMORE BRADFORD T purchased 187,512 shares across 3 transactions (Mar 12–16) for $1,196,908.98; blended avg $6.38; holdings now 1,941,759 shares (+10.7%).

Director Whitmore Bradford T executed 3 separate purchases totaling 187,512 shares for $1,196,908.98 between March 12–16, 2026, increasing his holdings by 10.7% to 1,941,759 shares. The blended average purchase price of $6.38 sits below the current price of $7.01, representing a near-term gain on the position. His prior trades at ULBI show 4 of 5 prior buys were well-timed at the 90-day mark, suggesting a pattern of entering at favorable inflection points. However, fundamentals warrant caution: the company posted net income of $-1,220,000.00 on quarterly revenue of $43,371,000.00, carries a P/E of 70.10, and has grown annual revenue only 3.7% year-over-year, indicating a loss-making business trading at a stretched valuation. The transaction's significance lies in the scale of capital deployed ($1.2M) and the insider's demonstrated timing skill at this ticker, offsetby the company's unprofitable status and elevated multiple.

Director Whitmore purchases 53,000 shares (53.0K) over 3 days at $5.68 avg; holdings rise to 1.24M shares (+4.5%)

Director Bradford T Whitmore executed 3 separate purchases totaling 53,000 shares for $300,902.22 between December 12–16, 2025, at prices ranging from $5.63 to $5.70 (blended average $5.68). His post-transaction holdings reached 1,235,631 shares, representing a 4.5% increase. At the current price of $5.79, the stock trades 36.6% below its 52-week high of $9.13, though up 4.1% over 30 days. His prior 4 measurable purchases at ULBI showed 0 of 4 well-timed at the 90-day mark, with outcomes ranging from -23.7% to -9.0% on the 90-day view. The company posted net income of $-1.2M in the latest quarter on $43.4M revenue, with a P/E of 57.90. This is a routine accumulation by a board member without scheduled trading plan disclosure, but the timing pattern at this ticker historically underperformed the broader market on 90-day horizons.

Director Janie Goddard buys 1,739 shares of ULBI at $5.75, adding to 7.7K share position; stock down -37.0% from 52-week high.

Director Janie Goddard purchased 1,739 shares at $5.75, increasing her stake by 29.3% to 7.7K shares. The stock has declined significantly, trading at -37.0% from its 52-week high of $9.13 and down 15.1% over the past 90 days, though it has recovered 3.4% in the past month. Her prior three purchases at ULBI show a mixed record: the most recent buy from June 2025 returned +12.2% over 30 days, but historical 90-day returns have been negative, with zero of her three prior ULBI trades producing positive 90-day returns. The company itself faces headwinds with negative net income of $-1.2M against $43.4M in quarterly revenue, and a P/E of 57.50. This buy occurs during a period of material stock weakness and against a backdrop of the insider's own poor timing on this ticker over a multi-year period.

Director Robert W. Shaw bought 1,750 shares of ULBI at $5.67; stock down 36.5% from 52-week high, cluster buy detected

Robert W. Shaw purchased 1,750 shares at $5.67, expanding his holdings by 2.5% to 71,000 shares. The stock has declined significantly: down 36.5% from its 52-week high of $9.13 and off 14.2% over the past 30 days. His same-ticker history shows mixed timing results—one prior buy delivered a 90d return of +41.0%, but two others yielded negative 90d returns. A cluster pattern is present: 2 other insiders also bought within the past 14 days, suggesting coordinated conviction among board members or management at depressed price levels. Fundamentals show the company is unprofitable (net income $-1.2M on revenue of $43.4M) with a stretched valuation (P/E of 58.00), creating context for why insider accumulation at these prices merits investor attention. The convergence of multiple insiders purchasing into weakness, combined with significant recent stock decline, warrants closer examination of whether this reflects non-public confidence or is a marker of the profitability challenges evident in the latest financials.

Director WHITMORE BRADFORD T bought 53,900 shares of ULBI at $4.97 on 2025-11-19; stock now $5.24, down 42.6% from 52-week high.

WHITMORE BRADFORD T purchased 53,900 shares at $4.97, increasing his position from 1,128,731 to 1,182,631 shares. The transaction occurred as ULBI trades near multi-month lows, down 21.2% over 30 days and 27.3% over 90 days from recent price levels. His prior trading activity at ULBI shows mixed timing outcomes: of five recent open-market purchases at this ticker, only one demonstrated a positive 90-day return, with the most recent three buys (August 19–21, 2025) each followed by 90-day declines ranging from 15.6% to 23.7%. The company reports a net loss of $1.2M on quarterly revenue of $43.4M, with a P/E ratio of 52.40, reflecting elevated valuation despite recent operational challenges. This purchase follows a pattern of accumulation during periods of weakness but does not yet demonstrate successful market timing specific to ULBI.

CEO Michael Edward buys 2,000 shares at $4.97 avg while stock -24.6% in 30 days; ULBI down 44.6% from 52-week high.

Manna Michael Edward, as President and CEO, executed 2 separate purchases totaling 2,000 shares for $9,933.00 ($4.97 blended average) on 2025-11-19, increasing his holdings by 8.7% to 24.9K shares. The transaction occurred during significant recent weakness: the stock is -24.6% over the prior 30 days and -44.6% from its 52-week high of $9.13, trading at $5.06. His same-ticker history shows mixed timing: 3 of his 5 prior ULBI buys yielded positive 90-day returns, though the most recent buy on 2025-05-13 posted +48.0% in 30 days before this current decline; his cross-ticker track record across all holdings shows 60% win rate at the 90-day mark with +31.2% average return. The company faces headwinds: net income is -$1.2M on $43.4M revenue, P/E stands at 50.60, and YoY revenue growth is only +3.7%. The transaction is noteworthy as a significant open-market commitment by the company's top executive during a steep drawdown, though near-term price momentum remains negative.

Director WHITMORE BRADFORD T purchased 58.7K shares (3 transactions) at blended $6.60 on Aug 19–21, raising stake 5.5%.

Director Whitmore Bradford T executed 3 separate purchases totaling 58,664 shares for $387,100.07 between August 19 and August 21, 2025, at prices ranging from $6.56 to $6.63 (blended average $6.60). This raises his post-transaction holdings to 1,128,731 shares, a +5.5% increase. The purchases occur during a period of stock weakness: the current price of $6.66 sits -40.4% below the 52-week high and -26.9% over 30 days. Notably, his prior 4 measurable buys at ULBI have all exhibited positive 90-day returns (ranging from +12.8% to +50.4%), establishing a ticker-specific pattern of well-timed accumulation. This multi-transaction filing does not indicate a single impulsive decision but a deliberate accumulation at depressed levels.